Phase I study of weekly low dose Paclitaxel for pancreato-biliary cancers after failure of gemcitabine and 5-FU

Phase I study of weekly low dose Paclitaxel for pancreato-biliary cancers after failure of gemcitabine and 5-FU - Palliative chemotherapy with paclitaxel for pancreato-biliary cancers

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008148

Enrollment

Registered

2012-06-14

Start date

2012-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreato-biliary cancers

Interventions

Paclitaxel

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patient with pancreatobiliary cancer after failure of gemcitabine and 5FU.

Exclusion criteria

Exclusion criteria: Patients with a history of anti-cancer agent taxane administration.

Design outcomes

Primary

Measure	Time frame
Determination of recommended dose	—

Secondary

Measure	Time frame
Assessment of safety, Prolonged survival after failur of S-1 and GEM, Response rate, Disease control rate, Adverse event	—

Countries

Japan

Contacts

Public ContactHidehiro Tajima

Kanazawa University Hospital Hepato-Biliary-Pancreatic Surgery

hidetaji@staff.kanazawa-u.ac.jp076-265-2362

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026